Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) a clinical-stage dermatology and oncology biopharmaceutical firm reported the presentation of PV-10 data at the Society for Immunotherapy of Cancer annual meeting.
The expert speaks
The published abstract stated that in the murine model considered regression of uncured pancreatic tumors by PV-10 IL injection in concomitant tumor backs the orientation of a systemic anti-tumor response. In addition, chemotherapy enhances the impact of IL PV-10 therapy. The presented poster added that the report may warrant a clinical study to assess the combination of IL PV-10 and gemcitabine in treatment of metastatic pancreatic cancer.
Eric Wachter, Ph.D., CTO of Provectus, stated that as per the American Cancer Society data, pancreatic cancer has surged 53,070 new cases projected in 2016 from 33,730 new cases in 2006 in the United States. In the same period, deaths jumped to 41,780 from 32,300, and it has turned to be the fourth most prevalent cause of cancer death in women and men alike. The 5-year inclusive survival rate is 8%. Hence, this is a segment in oncology with a growing and large unmet need.
Wachter added that the work posted by Pilon-Thomas and associates reveals that PV-10 has therapeutic action in murine representations of pancreatic cancer, and this is increased when intralesional PV-10 and systemic gemcitabine are combined, a standard chemotherapeutic means used to cure this disease. Backing this observation, their poster revealed that PV-10 produced interferon-gamma production, a mark of the orientation of an anti-tumor immune response, in association with relapse of uninjected bystander tumors.
They also revealed that myeloid derived suppressor cells dropped when GEM was utilized alone or along with PV-10. As MDSC have an inhibitory impact on numerous immune effector cells, comprising dendritic cells, NK T cells and CD8+ T cells, the apparent combination impact could result from lower immune suppression by GEM together with immunologic stimulation by PV-10. It has previously been demonstrated to result in tumor-specific anti-tumor immune responses in colorectal and melanoma carcinoma that comprises activation of CD8+ T cells.